Low grade ovarian is a difficult cancer to treat with chemotherapy.

So it is quite reassuring to note that a new drug combination is very promising in this setting .

Interim Results were revealed at the American Society of Clinical oncology conference in Chicago.

The study is continuing and the drugs are not available outside the study setting.

Hopefully, in the near future, the final study results of study would lead to this combination becoming standard of care in routine practice. Nothing guaranteed though !

References

Telegraph. New drug cocktail could double treatments for rare form of ovarian cancer

ASCO Chicago 2023: Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.